Cargando…
Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis
BACKGROUND: Differences in immunogenicity between mRNA SARS-CoV-2 vaccines have not been well characterized in patients undergoing dialysis. We compared the serologic response in patients undergoing maintenance hemodialysis after vaccination against SARS-CoV-2 with BNT162b2 (Pfizer-BioNTech) and mRN...
Autores principales: | Yau, Kevin, Chan, Christopher T., Abe, Kento T., Jiang, Yidi, Atiquzzaman, Mohammad, Mullin, Sarah I., Shadowitz, Ellen, Liu, Lisa, Kostadinovic, Ema, Sukovic, Tatjana, Gonzalez, Anny, McGrath-Chong, Margaret E., Oliver, Matthew J., Perl, Jeffrey, Leis, Jerome A., Bolotin, Shelly, Tran, Vanessa, Levin, Adeera, Blake, Peter G., Colwill, Karen, Gingras, Anne-Claude, Hladunewich, Michelle A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Impact Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053976/ https://www.ncbi.nlm.nih.gov/pubmed/35115375 http://dx.doi.org/10.1503/cmaj.211881 |
Ejemplares similares
-
Différences d’immunogénicité des vaccins anti-SRAS-CoV-2 mRNA-1273 (Moderna) et BNT162b2 (Pfizer-BioNTech) chez les patients dialysés
por: Yau, Kevin, et al.
Publicado: (2022) -
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
Publicado: (2021) -
Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
por: Islam, Nazmul, et al.
Publicado: (2022) -
COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273: Various toxicities: 13 case reports
Publicado: (2021) -
Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022)